Analyzing the Genotoxicity of Retroviral Vectors in Hematopoietic Cell Gene Therapy
View/ Open
Published Version
https://doi.org/10.1016/j.omtm.2017.10.002Metadata
Show full item recordCitation
Biasco, Luca, Michael Rothe, Hildegard Büning, and Axel Schambach. 2017. “Analyzing the Genotoxicity of Retroviral Vectors in Hematopoietic Cell Gene Therapy.” Molecular Therapy. Methods & Clinical Development 8 (1): 21-30. doi:10.1016/j.omtm.2017.10.002. http://dx.doi.org/10.1016/j.omtm.2017.10.002.Abstract
Retroviral vectors, including those derived from gammaretroviruses and lentiviruses, have found their way into the clinical arena and demonstrated remarkable efficacy for the treatment of immunodeficiencies, leukodystrophies, and globinopathies. Despite these successes, gene therapy unfortunately also has had to face severe adverse events in the form of leukemias and myelodysplastic syndromes, related to the semi-random vector integration into the host cell genome that caused deregulation of neighboring proto-oncogenes. Although improvements in vector design clearly lowered the risk of this insertional mutagenesis, analysis of potential genotoxicity and the consequences of vector integration remain important parameters for basic and translational research and most importantly for the clinic. Here, we review current assays to analyze biodistribution and genotoxicity in the pre-clinical setting and describe tools to monitor vector integration sites in vector-treated patients as a biosafety readout.Other Sources
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5684499/pdf/Terms of Use
This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAACitable link to this page
http://nrs.harvard.edu/urn-3:HUL.InstRepos:34493074
Collections
- HMS Scholarly Articles [17922]
Contact administrator regarding this item (to report mistakes or request changes)